Create account to read this article for free
Get free access to a limited number of articles.
Zealand Pharma reports promising results for dapiglutide
Zealand Pharma has presented positive topline results from a 28-week Phase Ib study of its GLP-1/GLP-2 receptor dual agonist dapiglutide, which achieved an average weight loss of 11,6 percent. The results are praised by Jefferies.
Notes
AstraZeneca updates on phase III study
Orexo maintains full-year forecast despite currency headwinds
BioGaia launches subsidiary for microbiome research
Isofol receives positive FDA feedback for arfolitixorin
BioArctic awarded Japanese prize for lecanemab
NEWSLETTER
NEWS
Biovica's blood test provides new answers for cancer care
Green light for PHI to step up its commercial strategy
Enzymatica's CEO comments on his resignation
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
